Penumbra, Inc.

NYSE:PEN

Sector

🏥 Health Care

Industries

🩺 Medical Instruments

🔬 Clinical Trials

💻 Computers

💻 Telehealth

Location

United States

Market Cap

USD 9.95 B

Share Price

USD 256.87

Avg Daily Volume

523,652

Change (1 day)

-0.05%

Change (1 year)

46.41%

Change (YTD)

8.16%

Penumbra, Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2025: USD 21.20 M

Penumbra, Inc. Depreciation And Amortization is USD 21.20 M for the Trailing 12 Months (TTM) ending March 31, 2025, a -24.83% change year over year. Depreciation and amortization are expense that reduces the value of tangible and intangible assets over their useful lives for tax and reporting purposes.

Penumbra, Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 28.20 M, a 12.04% change year over year.
Penumbra, Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 25.17 M, a 34.87% change year over year.
Penumbra, Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 18.66 M, a 39.24% change year over year.
Penumbra, Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 13.40 M, a 44.76% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Depreciation And Amortization	Dividends Paid	Common Stock Issued	Common Stock Repurchased

NYSE: PEN

Penumbra, Inc.

CEO	Mr. Adam Elsesser J.D.
IPO Date	Sept. 18, 2015
Location	United States
Headquarters	One Penumbra Place
Employees	4,500
Sector	🏥 Health Care
Industries Medical Instruments 🔬 Clinical Trials 💻 Computers 💻 Telehealth

Description

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.